As of 2026-09-11, NHC scores 42out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. NHC trades at $224.47, 179% above the band ceiling.
NHC scores 42 out of 100 on QNTM's five-factor model — a low-conviction reading — at 42 the factor profile is among the weaker names in the universe. Its strongest factor is momentum at 59 (solid), where price trend and relative strength are working in its favor, followed by sentiment at 51. The weakest is value at 19, where valuation looks stretched. Among Healthcare stocks it sits in the lower 40% of Healthcare names by composite.
On valuation, NHC is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 43. Same-sector names the model rates nearby include HALO, THC, HNGE.
This is a descriptive factor read on NHC, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where NHC sits on the model's measures today, and can change as new data arrives.
QNTM’s descriptive fair-value band for NHC runs $55.32–$80.32. Current price $224.47 sits 179% above the band ceiling. This is valuation context, not a price target.
QNTM rescores NHC and ~1,400 other names every session. Track it, get notified the moment it crosses a conviction tier, and see the full signal history.
Start free →QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.